Recce Pharmaceuticals Locks in Brazilian Patent Protection Through 2041
Recce Pharmaceuticals Brazil patent grant secures Family 4 protection for R327 and R529 anti-infectives through 2041 in South America's largest antibiotics market, expanding the company's global IP portfolio to seven jurisdictions.
Key Takeaways
- Brazil's National Institute of Industrial Property (INPI) has granted Recce Pharmaceuticals a Family 4 patent covering R327 and R529, extending protection through 2041 in South America's largest antibiotics market.
- This is Recce's seventh Family 4 patent globally, joining Australia, Canada, China, Hong Kong, Israel, and Japan, with additional PCT submissions still under review.
- The patent covers a broad range of indications including ABSSSI, Diabetic Foot Infections, Burn Wounds, VAP/HAP, UTIs, Gonorrhoea, Influenza, and SARS-CoV-2, across multiple delivery routes and formulations.
- Brazil's antibiotics market is projected to grow from USD 774.5 million in 2024 to USD 964.3 million by 2033, at a 2.4% CAGR, providing a long-term commercial runway for Recce's pipeline candidates.
- R327 holds FDA Qualified Infectious Disease Product (QIDP) designation with Fast Track status and 10 years of US market exclusivity post-approval, complementing the expanding global IP estate.
Breaking ASX Alerts Direct to Your Inbox
Join +20,000 subscribers receiving alerts.
Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.
- Breaking ASX announcements delivered within minutes
- Alerts delivered with expert analysis
- Optional text alert for subscribers
- No spam policy, unsubscribe any time
About the Publisher
StockWire X delivers fast, reliable, and actionable insights into significant developments across global markets, with coverage spanning technology, biotechnology, healthcare, financials, and emerging industries. Our mission is to provide clear, data-driven content that empowers investors to identify opportunities and make informed decisions ahead of the market.
Our network spans key financial and investment hubs worldwide, ensuring subscribers receive timely updates on market-moving announcements, news, macroeconomic trends, and corporate developments.
Use of Technology
We harness advanced technologies to enhance the speed, accuracy, and relevance of our reporting.
While technology accelerates our workflow, every piece of content is selected, validated, and published by human professionals, in accordance with best practices for accuracy, transparency, and investor value. This hybrid approach ensures speed without compromising editorial integrity.
Feedback and Accuracy
We are committed to accuracy and fairness in our reporting. If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.
Disclaimer
StockWire X provides readers with access to market news, educational content, and commentary from financial services professionals, industry experts, and companies (“Contributors”).
StockWire X does not hold an Australian Financial Services Licence (AFSL) and relies on the exemption available under section 911A(2)(eb) of the Corporations Act 2001 (Cth) in respect of any financial product advice provided.
Any advice or information published by StockWire X is general in nature only and has been prepared without taking into account your personal objectives, financial situation, or needs. Before acting on any information, you should consider whether it is appropriate for your circumstances and seek independent, licensed financial advice. You should also obtain and read any relevant Product Disclosure Statement (PDS) or other offer document before making an investment decision.
StockWire X makes no guarantee as to the accuracy, completeness, or timeliness of the information provided, and accepts no responsibility for any loss arising from reliance on it. All content is published in good faith for informational purposes only.
Disclosure
StockWire X may have commercial relationships with some contributors or companies mentioned in our content. Any such relationships will be disclosed where relevant.
If you believe any information we have published is inaccurate, incomplete, or misleading, please contact us at admin@stockwirex.com so we can review and address the matter promptly.